MegaPro Biomedical Co., Ltd

NT$14.35As of Sun 8 Nov 2026, 12:00 UTC

TPEx:6827Healthcare

Country Taiwan

PE (Fwd) —

TSR 5Y CAGR (13.07%)

Div yield —

ROE (51.01%)

Biotechnology

Beta (5Y) —

PE TTM —

TSR TTM (14.58%)

Mkt cap NT$1.741B

ROIC (86.79%)

SE Grade™

—

Value

—

Quality

Moat

1Y Price

Reference

NT$15

—

5.36%

—

—

TTM

FYE 31 Dec TWD

FY2022

FY2023

FY2024

FY2025

FY2026E

Trend

5Y

10Y

Peers

◌—

RevenueNT$M

—

—

—

—

—

—

◌—

0.018

0.014

◌—

0.012

(22.22%)

—

—

—

Revenue growth%

—

—

—

—

—

—

—

—

(22.22)

—

(11.81)

(22.22)

—

—

—

Gross margin%

—

—

—

—

—

—

—

100.00

100.00

—

100.00

100.00

—

—

—

Operating margin%

—

—

—

—

—

—

—

(780483.33)

(1287092.86)

—

(100.00)

(1033788.10)

—

—

—

Net margin%

—

—

—

—

—

—

—

(708600.00)

(1171721.43)

—

(100.00)

(940160.71)

—

—

—

P/E ratio (avg)x

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

EV/EBITx

—

—

—

—

—

—

—

—

—

—

—

—

—

—

(12.37)

FCF yield (avg)%

—

—

—

—

—

—

(7.77)

(6.72)

(10.16)

(11.68)

—

(8.96)

—

—

—

FCF margin%

—

—

—

—

—

—

—

(578255.56)

(1038121.43)

—

(100.00)

(808188.49)

—

—

0.981

FCF / Net incomex

—

—

—

—

—

—

0.862

0.816

0.886

0.981

—

0.874

—

—

(86.79)

ROIC%

—

—

—

—

—

—

(67.24)

(84.84)

(132.27)

(86.79)

(0.01)

(85.82)

—

—

(51.01)

Return on equity%

—

—

—

—

—

—

(35.54)

(43.72)

(69.30)

(51.01)

—

(47.37)

—

—

(42.70)

Return on assets%

—

—

—

—

—

—

(32.60)

(43.30)

(73.13)

(42.70)

—

(43.00)

—

—

(1.81)

EPSNT$

—

—

—

—

—

—

(1.89)

(2.15)

(2.50)

(1.81)

—

—

—

—

27.68

EPS growth%

—

—

—

—

—

—

—

(14.16)

(16.23)

27.68

99.99

(14.16)

—

—

3.99

Bookvalue per shNT$

—

—

—

—

—

—

5.31

4.54

3.12

3.99

3.99

(9.06%)

—

—

(1.77)

FCF per shareNT$

—

—

—

—

—

—

(1.63)

(1.76)

(2.22)

(1.77)

—

—

—

—

—

Dividend per shNT$

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

Div yield (avg)%

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

Payout ratio%

—

—

—

—

—

—

—

—

—

—

—

—

—

—

121.3

Shares (diluted)M

—

—

—

—

—

—

59.24

59.24

65.56

65.82

◌65.82

3.57%

—

—

(0.40)

Buyback yield%

—

—

—

—

—

—

—

—

(10.65)

(0.40)

◌—

(0.40)

—

—

0.011

D/E ratiox

—

—

—

—

—

—

0.035

0.031

0.028

0.011

0.011

0.029

—

—

1.631

Enterprise valueNT$B

—

—

—

—

—

—

1.105

1.431

1.349

0.891

0.835

(6.95%)

—

—

—

LT debtNT$M

—

—

—

—

—

—

—

—

—

—

—

—

—

—

Peers (US$26.19M)

Cap (US$)

PE

27.69M

18.25x

Holy Stone Healthcare…

27.03M

—

GeneReach Biotechnolog…

25.76M

—

Xbrane Biopharma AB…

26.46M

—

Capital

TTM

5Y

10Y

Leveragex

—

—

—

EBIT/Intx

(866.6)

(437.9)

(437.9)

Own earn%

—

—

—

Sh yield%

(0.40)

(0.40)

(0.40)

Owners

Insiders/Inst%

6.16

19.66

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

0/4

Revenue growth years

—

EPS growth years

1/3

Dividend streakyrs

0

Op margin range%

—

$1 testx

—

Incr. ROIC%

—

MegaPro Biomedical Co., Ltd, a biotech company, focuses on the development of nano drugs.

Revenue by segment

No breakdown available

Asset mix

Share

Trend

Other

59.74%

Cash and investments

40.26%

Reinvestment returns

No breakdown available